BUSINESS COMBINATION AND DECONSOLIDATION OF SUBSIDIARY (Details Narrative) - USD ($)			9 Months Ended	12 Months Ended
	Jun. 05, 2020	May 14, 2019	Sep. 30, 2021	Dec. 31, 2020
Total potential shares to be issued		32,072,283		26,372,283
Warrants issue purchase additional shares				4,143,706,000,000
Upfront payment consideration		5,700,000
Claw back shares		7,128,913
Acheivment shares		3,207,228
Earnout shares		8,018,071
Estimated acquisition costs			$ 4,000,000.0
Convertible Note [Member]
Debt instrument converted amount, principal				$ 14,600,000
CHI [Member]
Total purchase price, shares		8,410,875
Common stock shares including escrow shares decriptions	a) all 7,128,913 shares held in escrow were released to the Holders as of the Release Effective Date, of which 140,828shares were returned to the Company for cancellation in consideration for the Company committing to pay certain outstanding liabilities, (b) of the 11,225,299 total shares issuable pursuant to the earn-out provisions in the CHI Merger Agreement, 5,612,654 shares were issued to the Holders as of the Release Effective Date (310,821 of which were assigned back to the Company as of the Release Effective Date) and the obligation of the Company to issue any further earn-out shares was terminated, and (c) certain Holders exercised warrants issued in the CHI Merger to purchase 708,467 shares of Common Stock on the Release Effective Date at a price of $2.00 per share (which reflects a reduced exercise price as a result of the Warrant Amendment) for gross proceeds to the Company of approximately $1.4million and the remaining warrants to purchase 7,309,605 shares of Common Stock issued in the CHI Merger expired on the Release Effective Date as a result of an amendment of such warrants effected pursuant to the Warrant Amendment.	up to 8,018,071 shares issuable upon exercise of warrants (“Acquisition Warrant Shares”) that become exercisable upon achieving certain revenue goals between the second and fourth anniversary of the Closing Date at an exercise price of $5.01 per share, exercisable, to the extent vested, for five years from the Closing Date. In exchange for the assets and liabilities acquired, the Company received an investment of $2 million from Chemistry Holdings pursuant to a convertible note
Gross proceeds	1,400,000.0
Warrants purchase upon common stock	7,309,605		708,467
Purchase price for acquision		$ 34,100,000
Preliminary purchase price desriptions			The preliminary total purchase price was determined based on the following: i) $1 million of the Upfront Payment ii) Company’s closing price ($1.38) on October 2, 2020 for the closing merger consideration shares; and iii) the estimated fair value using the Monte-Carlo simulation of stock price correlation, and other variables over a 24 month performance period applied to the Clawback Shares
October 2, 2020 [Member] | Sera labs [Member]
Closing Merger Consideration Shares, shares			6,909,091
Contingent Consideration Shares (Clawback Shares), shares			5,988,024
Upfront Consideration Shares, value			$ 100,000
Aggregate amount			$ 20,000,000
Total purchase price, shares			12,897,115
Liability Contingent shares consideration			$ 3,100,000.0
Fair value of preliminary purchase price			$ 14,200,000.0
Acquisition descriptions			The Company acquired Sera Labs through the issuance of shares of Common Stock of the Company with $1 million of cash consideration to be provided. The preliminary total purchase price was determined based on the following: i) $1 million of the Upfront Payment ii) Company’s closing price ($1.38) on October 2, 2020 for the closing merger consideration shares